Hyderabad/Bangalore, NFAPost: Turbostart, a global sector-agnostic venture capital platform, has made a $1 million investment in Ai Health Highway as part of its Pre-Series A round funding.
Ai Health Highway is a company that focuses on providing tech-enabled screening tools that help in the early detection of non-communicable diseases (NCDs) and improving healthcare accessibility through India’s first Ai-enabled stethoscope, AiSteth.
This investment is part of a larger $1.5 million funding, including co-investment from notable investors Rainmatter by Zerodha, The Chennai Angels, BITS BioCyTiH Foundation along with other angel investors. This crucial funding will empower Ai Health Highway to solidify its presence in India, accelerate regulatory approvals internationally, and broaden its AI/ML offerings in the Cardio-Respiratory domain.
AiSteth, India’s first AI-enabled stethoscope, is revolutionising cardiac care by assisting healthcare professionals and non-specialists in interpreting heart sounds to support accurate clinical decisions. Utilizing advanced AI and signal processing, AiSteth transforms traditional stethoscopes into powerful screening tools capable of detecting life-threatening cardiac disorders at an early stage.
The AI-enabled stethoscope seamlessly integrates into existing workflows, equipping primary care providers with high-quality heart sound capture, analysis, and data-sharing capabilities, thereby enhancing the accessibility and affordability of healthcare solutions.
Founded in 2018, Ai Health Highway is on a mission to reduce global premature deaths due to NCDs by 30% by 2030. NCDs account for over 41 million deaths annually, highlighting the need for early detection and intervention.
Turbostart Founder and CEO Venkat Raju stated the company is thrilled to support Ai Health Highway and its exceptional founding team, who bring together a powerful blend of medical expertise, business acumen, and technological innovation.
“Their work goes beyond upgrading the stethoscope – they’re reimagining screening tools to make healthcare more accessible in the modern age. Their smart stethoscope technology has the potential to bring quality screenings to underserved communities, democratising access to early detection,” said Turbostart Founder and CEO Venkat Raju.
He also said the company is excited to see how they will transform healthcare accessibility, creating meaningful impact in an industry where change is not just welcome, but necessary.”
AI Health Highway Founder Dr (Maj) Satish S Jeevannavar said the company is delighted to announce Turbostart as the Lead Investor for our Pre-Series A round, joined by co-investors Rainmatter by Zerodha and BITS BioCyTiH Foundation.
“Our existing investors, The Chennai Angels, along with other angel investors, have also participated in this round. We are thrilled to collaborate with Turbostart on this vital mission to tackle NCDs. The expertise of their seasoned professionals and Centers of Excellence will be invaluable as we navigate the complex global healthcare landscape,” said AI Health Highway Founder Dr (Maj) Satish S Jeevannavar.
In addition to this investment, Turbostart has a proven track record of supporting tech-first startups across various sectors. Over the past five years, Turbostart has facilitated investments of more than USD 50 million across more than 50 innovative startups. This commitment highlights Turbostart’s continued dedication to supporting the growth and development of the startup ecosystem, providing personalized mentorship, access to five centers of excellence, and a vast network spanning India, the US, MEA, and Singapore to support the development of thriving enterprises.
